Immediate Impact

61 standout
Sub-graph 1 of 23

Citing Papers

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
1 intermediate paper

Works of K. Gattringer being referenced

Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract
2012
Gemella morbillorum Bacteremia after Anti-Tumor Necrosis Factor Alpha as Acne Inversa Therapy
2011

Author Peers

Author Last Decade Papers Cites
K. Gattringer 84 25 24 140 111 11 307
M Elliott 45 3 81 49 18 8 298
Shadi Ahmadmehrabi 22 15 51 16 16 10 345
Conor J. Bloxham 13 118 15 23 36 12 258
Craig H. Steffee 47 20 62 16 8 16 309
H. Zahra 21 132 2 61 28 10 264
Jessica Stevenson 24 5 12 8 19 12 347
N’dri Juliette Kadiane-Oussou 22 166 2 58 21 8 274
Orsolya Huszár 20 2 157 32 17 10 365
Seil Sagar 27 16 37 6 24 7 351
Pamir Çerçi 12 31 35 9 9 18 356

All Works

Loading papers...

Rankless by CCL
2026